Accueil   Diary - News   All news ElsaLys Biotech and the prestigious German cancer research institute DKFZ initiate the development of ELB021 in B-Cell leukemia with the support of EU

ElsaLys Biotech and the prestigious German cancer research institute DKFZ initiate the development of ELB021 in B-Cell leukemia with the support of EU

  • ELB021 is a proprietary first-in-class monoclonal antibody targeting CD160, a multifunctional target expressed on both immune & leukemia cells.
  • With the support of the EU program Eurostar1, ELSALYS BIOTECH & DKFZ initiate the preclinical development of this next-generation immunotherapy which acts both as immune checkpoint inhibitor and cytotoxic antibody.
  • Once validated, ELB021 should enter clinical development in 2020.

 

Lyon, FRANCE, 18 July 2017, ELSALYS BIOTECH, an emerging player in the field of oncology & ophthalmology, announces today that ELB021, its first-in-class monoclonal antibody targeting the cell-surface receptor CD160, has entered into a preclinical collaboration with DKFZ (the “LeukeMab Project”) under a EU-sponsored program Eurostars*.

 

In-licensed by ELSALYS BIOTECH from Inserm Transfert in February 2016, ELB021 is a next-generation immunotherapy antibody combining complementary mechanisms of action that could improve the efficacy/toxicity cancer treatment ratio, notably in B-cell leukemias such as Chronic Lymphoid and Hairy-Cell Leukemias (CLL and HCL). Early studies have already shown that ELB021:

 

  • stimulates innate & adaptive anti-tumor immune response;
  • eliminates selectively cancer cells expressing CD160 (normal B cells doesn’t express CD160 while the receptor is overexpressed in 98 % of CLL and in 100 % of HCL cells).

 

 

 

 

 Read the press release